Discover 1,423 paid clinical trials in Akron, Ohio. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 1,423
Active & Responsive
A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies
for
Healthy
Location: South Euclid OH, Cleveland OH, Pittsburgh PA,
Sponsor: Pfizer
Sex: All
Age: 0 - 49
Code: NCT07160244
Phase3, Recruiting
Active & Responsive
A Study to Learn About a Vaccine Against E Coli in Healthy Adults
for
Healthy Participants
Location: South Euclid OH, Cincinnati OH, Knoxville TN,
Sponsor: Pfizer
Sex: All
Age: 18 - 64
Code: NCT07122986
Phase1, Recruiting
Active & Responsive
Multi-Site Detection of Barrett's Esophagus in Patients Without Chronic GERD Symptoms
for
Barrett Esophagus, Gastroesophageal Reflux,
Location: Cleveland OH, Baltimore MD, Chapel Hill NC, Aurora CO
Sponsor: Case Comprehensive Cancer Center
Sex: All
Age: 50+
Code: NCT06687603
Recruiting
Active & Responsive
Is Intraperitoneal Drainage Necessary Following Distal Pancreatectomy?
for
Cyst of Pancreas, Pancreatectomy, Pancreas Neoplasm
Location: Cleveland OH
Sponsor: Case Comprehensive Cancer Center
Sex: All
Age: 18+
Code: NCT05720338
Phase3, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Active & Responsive
A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)
for
Urothelial Carcinoma
Location: Cleveland OH, Pittsburgh PA, Toronto, Indianapolis IN,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT05562830
Phase1, Phase2, Recruiting
Active & Responsive
KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
for
Bladder Cancer
Location: Cleveland OH, Chicago IL, Salt Lake City UT,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT07232602
Phase1, Phase2, Recruiting
Active & Responsive
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
Location: Cleveland OH, Pittsburgh PA, Columbus OH, Detroit MI,
Sponsor: Black Diamond Therapeutics, Inc.
Sex: All
Age: 18+
Code: NCT07326566
Phase2, Recruiting
Active & Responsive
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
for
Non-small Cell Lung Cancer
Location: Cleveland OH, Detroit MI, Fairfax VA,
Sponsor: BioNTech SE
Sex: All
Age: 18+
Code: NCT07111520
Phase1, Phase2, Recruiting
Active & Responsive
Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy
A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study)
for
PIK3CA-Related Overgrowth Spectrum (PROS),
Location: Cleveland OH, Cincinnati OH, Grand Rapids MI,
Sponsor: Relay Therapeutics, Inc.
Sex: All
Age: 2+
Code: NCT06789913
Phase2, Recruiting
Active & Responsive
Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer